Scorpion Therapeutics is a precision clinical stage oncology company developing small molecule drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy. The company has done significant deals with Astra Zeneca and Pierre Fabre and is well funded to rapidly develop its portfolio of drugs against known, high-impact oncogenes.